Estimation of the spectrum and severity of COVID-19-associated metabolic changes in patients with non-alcoholic fatty liver disease

Capa

Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

COVID-19 pandemic has posed new questions for physicians and researchers regarding the management of patients with non-alcoholic fatty liver disease (NAFLD). In addition to direct cytopathic effect, SARS-CoV-2 can induce a cascade of metabolic disorders, including dyslipidemia.

The aim: to perform a comprehensive estimation of the spectrum and severity of metabolic changes associated with COVID-19 in patients with NAFLD in the post-COVID period.

Material and methods. Retrospective cohort study included 73 patients with NAFLD, 22 of whom had COVID-19 from March 2020 to February 2021. The participants were analyzed for parameters of lipid spectrum, glycemic profile, inflammatory markers, and liver function.

Results. In patients who had COVID-19, comparatively with patients who did not have it, a statistically significant increase in the level of total cholesterol, low-density lipoprotein cholesterol, triglycerides, cholesterol not associated with high-density lipoproteins, glucose, glycated hemoglobin, C-reactive protein, and ferritin, as well as a decrease in the level of high-density lipoprotein cholesterol relatively to their baseline levels in 2019 was found.

Conclusion. COVID-19 in patients with NAFLD is associated with a high frequency and a wide range of metabolic disorders that potentially affect the progression of liver damage. Obtained data dictate the need for careful monitoring of metabolic parameters and optimization of therapeutic approaches in this group of patients.

Texto integral

Acesso é fechado

Sobre autores

Ksenia Zhuk

Privolzhsky Research Medical University of the Ministry of Healthcare of Russia

Autor responsável pela correspondência
Email: zhukks@rambler.ru
ORCID ID: 0009-0007-7413-5046
Código SPIN: 4726-3959

MD, assistant at the Department of therapy and cardiology

Rússia, Nizhny Novgorod

Ekaterina Tarlovskaya

Email: etarlovskaya@mail.ru
ORCID ID: 0000-0002-9659-7010
Código SPIN: 5007-4647
Scopus Author ID: 16305274900

MD, Dr. Sci. (Medicine), professor, head of the Department of therapy and cardiology

Rússia

Tatyana Vlasova

Email: taniavlasova@yandex.ru
ORCID ID: 0009-0005-5856-0208
Código SPIN: 9034-6670
Scopus Author ID: 57217079352

MD, PhD (Medicine), associate professor of the Department of therapy of the Faculty of continuous professional education

Rússia

Bibliografia

  1. Agarwal A., Chen A., Ravindran N. et al. Gastrointestinal and liver manifestations of COVID-19. J Clin Exp Hepatol. 2020; 10(3): 263–65. https://doi.org/10.1016/j.jceh.2020.03.001. PMID: 32405183. PMCID: PMC7212283.
  2. Ильченко Л.Ю., Никитин И.Г., Федоров И.Г. COVID-19 и поражение печени. Архивъ внутренней медицины. 2020; 10(3): 188–197. [Ilchenko L.Yu., Nikitin I.G., Fedorov I.G. COVID-19 and liver damage. Arkhiv vnutrenney meditsiny = Archive of Internal Medicine. 2020; 10(3): 188–197 (In Russ.)]. https://doi.org/10.20514/2226-6704-2020-10-3-188-197. EDN: ABJPTS.
  3. Мехтиев С.Н., Мехтиева О.А., Берко О.М. Поражение печени при COVID-19: эпидемиология, патогенез, лечение. Эффективная фармакотерапия. 2022; 18(22): 86–93. [Mekhtiev S.N., Mekhtieva O.A., Berko O.M. Liver damage in COVID- 19: Epidemiology, pathogenesis, treatment. Effektivnaya farmakoterapiya = Effective Pharmacotherapy. 2022; 18(22): 86–93 (In Russ.)]. https://doi.org/10.33978/2307-3586-2022-18-22-86-92. EDN: CDUHYQ.
  4. Ding Z.-Y., Li G.-X., Chen L. et al.; Tongji Multidisciplinary Team for Treating COVID-19 (TTTC). Association of liver abnormalities with in-hospital mortality in patients with COVID-19. J Hepatol. 2021; 74(6): 1295–1302. https://doi.org/10.1016/j.jhep.2020.12.012. PMID: 33347952. PMCID: PMC7749734.
  5. Синякин И.А., Андриевская И.А., Ишутина Н.А., Смирнова Н.А. COVID-19 ассоциированная дислипидемия: роль липидов и жирных кислот в патогенезе SARS-Cov-2 инфекции. Бюллетень физиологии и патологии дыхания. 2022; (83): 107–118. [Sinyakin I.А., Аndrievskaya I.А., Ishutina N.А., Smirnova N.А. COVID-19-associated dyslipidemia: The role of lipid and fatty acids in the pathogenesis of SARS-Cov-2 infection 2022. Byulleten’ fiziologii i patologii dyhaniya = Bulletin of Physiology and Pathology of Respiration. 2022; (83): 107–118 (In Russ.)]. https://doi.org/10.36604/1998-5029-2022-83-107-118. EDN: PEBXUE.
  6. Argenziano M.G., Bruce S.L., Slater C.L. et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: Retrospective case series. BMJ. 2020: 369: m1996. https://doi.org/10.1136/bmj.m1996. PMID: 32471884. PMCID: PMC7256651.
  7. Kuswardhani R.A.T., Henrina J., Pranata R. et al. Charlson comorbidity index and a composite of poor outcomes in COVID-19 patients: A systematic review and meta-analysis. Diabetes Metab Syndr. 2020; 14(6): 2103–9. https://doi.org/10.1016/j.dsx.2020.10.022. PMID: 33161221. PMCID: PMC7598371.
  8. Bakaloudi D.R., Barazzoni R., Bischoff S.C. et al. Impact of the first COVID-19 lockdown on body weight: A combined systematic review and a meta-analysis. Clin Nutr. 2022; 41(12): 3046–54. https://doi.org/10.1016/j.clnu.2021.04.015. PMID: 34049749. PMCID: PMC8056819.
  9. Ahmed H.O. The impact of social distancing and self-isolation in the last corona COVID-19 outbreak on the body weight in Sulaimani governorate – Kurdistan/Iraq, a prospective case series. Ann Med Surg (Lond). 2020: 59: 110–17. https://doi.org/10.1016/j.amsu.2020.09.024. PMID: 32963773. PMCID: PMC7499371.
  10. Bizkarguenaga M., Bruzzone C., Gil-Redondo R. et al. Uneven metabolic and lipidomic profiles in recovered COVID-19 patients as investigated by plasma NMR metabolomics. NMR Biomed. 2022; 35(2): e4637. https://doi.org/10.1002/nbm.4637. PMID: 34708437. PMCID: PMC8646702.
  11. Washirasaksiri C., Sayabovorn N., Ariyakunaphan P. et al. Long-term multiple metabolic abnormalities among healthy and high-risk people following nonsevere COVID-19. Sci Rep. 2023; 13(1): 14336. https://doi.org/10.1038/s41598-023-41523-5. PMID: 37653091. PMCID: PMC10471587.
  12. Арутюнов Г.П., Тарловская Е.И., Арутюнов А.Г. с соавт. Динамика показателей липидного профиля после острого периода COVID-19. Субанализ международного регистра «Анализ динамики коморбидных заболеваний у пациентов, перенесших инфицирование SARS-CoV-2 (АКТИВ SARS-CoV-2)» (12 месяцев наблюдения). Российский кардиологический журнал. 2024; 29(3): 51–63. [Arutyunov G.P., Tarlovskaya E.I., Arutyunov A.G. et al. Lipid profile changes after the acute COVID-19 period. Sub-analysis of the International Registry “Dynamics Analysis of Comorbidities in SARS-CoV-2 Survivors (AKTIV SARS-CoV-2)” (12-month follow-up). Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2024; 29(3): 51–63 (In Russ.)]. https://doi.org/10.15829/1560-4071-2024-5716. EDN: ANRAPN.
  13. Baker J., Ayenew W., Quick H. et al. High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. J Infect Dis. 2010; 201(2): 285–92. https://doi.org/10.1086/649560. PMID: 19954384. PMCID: PMC2798007.
  14. Sorokin A.V., Karathanasis S.K., Yang Z.-H. et al. COVID-19-Associated dyslipidaemia: Implications for mechanism of impaired resolution and novel therapeutic approaches. FASEB J. 2020; 34(8): 9843–53. https://doi.org/10.1096/fj.202001451. PMID: 32588493. PMCID: PMC7361619.
  15. Ибраева Ж.Б., Айткулуев Н.С., Макембаева Ж.И. с соавт. Коронавирусная инфекция COVID-19 и поражение печени. Международный журнал прикладных и фундаментальных исследований. 2021; (9): 17–21. [Ibraeva Zh.B., Aytkuluev N.S., Makembaeva Zh.I. et al. Coronavirus infection COVID-19 and liver damage. Mezhdunarodnyy zhurnal prikladnykh i fundamental’nykh issledovaniy = International Journal of Applied and Basic Research. 2021; (9): 17–21 (In Russ.)]. https://doi.org/10.17513/mjpfi.13266. EDN: NVBNGT.
  16. Wang X., Lei J., Li Z., Yan L. Potential effects of coronaviruses on the liver: An update. Front Med (Lausanne). 2021; 8: 651658. https://doi.org/10.3389/fmed.2021.651658. PMID: 34646834. PMCID: PMC8502894.
  17. Hegyi P.J., Váncsa S., Ocskay K. et al. Metabolic associated fatty liver disease is associated with an increased risk of severe COVID-19: A systematic review with meta-analysis. Front Med (Lausanne). 2021; 8: 626425. https://doi.org/10.3389/fmed.2021.626425. PMID: 33777974. PMCID: PMC7994270.
  18. Feng G., Zheng K.I., Yan Q.-Q. et al. COVID-19 and liver dysfunction: Current insights and emergent therapeutic strategies. J Clin Transl Hepatol. 2020; 8(1): 18–24. https://doi.org/10.14218/JCTH.2020.00018. PMID: 32274342. PMCID: PMC7132016.
  19. Yu D., Du Q., Yan S. et al. Liver injury in COVID-19: Clinical features and treatment management. 2021; 18(1): 121. https://doi.org/10.1186/s12985-021-01593-1. PMID: 34108015. PMCID: PMC8188532.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2025